1. Home
  2. VRAX vs AIMD Comparison

VRAX vs AIMD Comparison

Compare VRAX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • AIMD
  • Stock Information
  • Founded
  • VRAX 2013
  • AIMD 1984
  • Country
  • VRAX United Kingdom
  • AIMD United States
  • Employees
  • VRAX N/A
  • AIMD N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AIMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • AIMD Health Care
  • Exchange
  • VRAX Nasdaq
  • AIMD Nasdaq
  • Market Cap
  • VRAX 7.3M
  • AIMD 8.5M
  • IPO Year
  • VRAX 2022
  • AIMD N/A
  • Fundamental
  • Price
  • VRAX $1.90
  • AIMD $0.74
  • Analyst Decision
  • VRAX
  • AIMD
  • Analyst Count
  • VRAX 0
  • AIMD 0
  • Target Price
  • VRAX N/A
  • AIMD N/A
  • AVG Volume (30 Days)
  • VRAX 293.5K
  • AIMD 380.6K
  • Earning Date
  • VRAX 02-05-2025
  • AIMD 03-07-2025
  • Dividend Yield
  • VRAX N/A
  • AIMD N/A
  • EPS Growth
  • VRAX N/A
  • AIMD N/A
  • EPS
  • VRAX N/A
  • AIMD N/A
  • Revenue
  • VRAX $84,872.00
  • AIMD $40,633.00
  • Revenue This Year
  • VRAX $5,169.18
  • AIMD N/A
  • Revenue Next Year
  • VRAX $66.97
  • AIMD N/A
  • P/E Ratio
  • VRAX N/A
  • AIMD N/A
  • Revenue Growth
  • VRAX 7.03
  • AIMD N/A
  • 52 Week Low
  • VRAX $0.60
  • AIMD $0.40
  • 52 Week High
  • VRAX $9.00
  • AIMD $3.10
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 49.13
  • AIMD 59.44
  • Support Level
  • VRAX $1.58
  • AIMD $0.57
  • Resistance Level
  • VRAX $2.10
  • AIMD $0.77
  • Average True Range (ATR)
  • VRAX 0.25
  • AIMD 0.06
  • MACD
  • VRAX 0.01
  • AIMD -0.00
  • Stochastic Oscillator
  • VRAX 47.88
  • AIMD 68.48

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Share on Social Networks: